Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2021

Feb 17, 2021

30016_dirs_2021-02-17_51daad0d-7553-47f7-992e-dcd5b13195a8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2021-02-14

Reporting Person: MAZELSKY JONATHAN JAY (Director, President & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-14 Common Stock M 737 Acquired 42164 Direct
2021-02-14 Common Stock M 459 Acquired 42623 Direct
2021-02-14 Common Stock M 505 Acquired 43128 Direct
2021-02-14 Common Stock M 435 Acquired 43563 Direct
2021-02-14 Common Stock M 974 Acquired 44537 Direct
2021-02-14 Common Stock F 1447 $544.08 Disposed 43090 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-14 Non-Qualified Stock Option (right-to-buy) $544.08 A 17674 Acquired 2031-02-13 Common Stock (17674) Direct
2021-02-14 Premium Non-Qualified Stock Option (right-to-buy) $598.4880 A 9717 Acquired 2021-02-13 Common Stock (9717) Direct
2021-02-14 Premium Incentive Stock Option (right-to-buy) $598.4880 A 183 Acquired 2031-02-13 Common Stock (183) Direct
2021-02-14 Restricted Stock Unit $ A 2757 Acquired Common Stock (2757) Direct
2021-02-14 Restricted Stock Unit $ M 737 Disposed Common Stock (737) Direct
2021-02-14 Restricted Stock Unit $ M 459 Disposed Common Stock (459) Direct
2021-02-14 Restricted Stock Unit $ M 505 Disposed Common Stock (505) Direct
2021-02-14 Restricted Stock Unit $ M 435 Disposed Common Stock (435) Direct
2021-02-14 Restricted Stock Unit $ M 974 Disposed Common Stock (974) Direct

Footnotes

F1: Includes 14 shares purchased under the Issuer's Employee Stock Purchase Plan on December 31, 2020.

F2: Closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021.

F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2022.

F4: Grant of option at a 110% premium to the closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021 to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2022.

F5: Grant of option at a 110% premium to the closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021 to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant.

F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022.

F7: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2017.

F8: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018.

F9: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019.

F10: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020.

F11: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021.

F12: Not applicable.